The Medical Advisor

In 2023, Dr Justus Hope reported on a case of Stage IV Colon Cancer that appeared hopeless . The gentleman, Rick, had widespread metastatic disease affecting the liver and lymph nodes and was told his cancer was “unsurvivable.” At most, he had six months left, according to his oncologist. Following adding Ivermectin, his tumor markers dropped from 1489 to 4.7, and his metastases calcified and shrunk. This was believed due to the anti-metastatic effect of Ivermectin as it suppresses the WnT Pathway, which cancer stem cells rely upon.   Dr. Tess Lawrie recently reported on a case of ovarian metastatic cancer with subsequent involvement of the peritoneum – a common spread area. Despite an initial tumor marker (Ca125) level of 288, following Ivermectin and three (9 weeks) chemotherapy sessions, her Ca125 level dropped to 22. There was a substantial regression with no trace of tumor on the peritoneum. Related:  The Surprising Potential of Ivermect...

AlphaFold is a significant advancement in the field of computational biology, developed by DeepMind, an AI research lab. Here's a concise overview: Purpose: AlphaFold predicts the 3D structure of proteins from their amino acid sequences, addressing one of the biggest challenges in biology known as the protein folding problem. Impact :  Scientific Research: It has accelerated research by providing structural insights into proteins, which are crucial for understanding their functions, designing drugs, and exploring biological mechanisms. Drug Discovery: By predicting protein structures, AlphaFold aids in identifying potential drug targets, understanding disease mechanisms, and designing new medications more efficiently. Technological Approach:  AlphaFold uses deep learning techniques, including neural networks trained on vast amounts of protein sequence data. It essentially learns from existing protein structures to predict new ones. It combines evolutionary, physical, and geome...

Medically Reviewed by: OneDayMD Editorial Team Last Updated: April 2026 Abstract Glioblastoma and other high-grade brain tumors remain among the most lethal malignancies, characterized by aggressive growth, therapeutic resistance, and near-universal recurrence despite multimodal standard-of-care treatment. In recent years, drug repurposing has emerged as a promising strategy to accelerate the identification of novel anticancer therapies. Among these, the antiparasitic agents ivermectin and mebendazole have attracted increasing attention due to their demonstrated anticancer activity in preclinical models, including effects on cancer stem cells, tumor metabolism, microtubule dynamics, and signaling pathways relevant to glioma progression. This article presents a compilation of over 100 real-world case reports compiled between 2019 and 2026, involving patients with glioblastoma, astrocytoma, and other intracranial tumors who incorporated ivermectin and/or mebendazole into their treatmen...